144
Participants
Start Date
April 30, 2002
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
Gemcitabine
Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
Capecitabine
Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
Vinorelbine
Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
University Hospital of Crete, Heraklion
University General Hospital of Alexandroupolis, Dept. of Medical Oncology, Alexandroupoli
"IASO General Hospital of Athens, 1st Dept. of Medical Oncology", Athens
"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dept. of Internal Medicine", Athens
"Marika Iliadis Hospital of Athens, Dept. of Medical Oncology", Athens
401 Military Hospital of Athens, Athens
Air Forces Military Hospital of Athens, Athens
State General Hospital of Larissa, Dept. of Medical Oncology, Larissa
"Metaxa's Anticancer Hospital of Piraeus, 1st Dept. of Medical Oncology", Piraeus
"Theagenion Anticancer Hospital of Thessaloniki, 2nd Dept. of Medical Oncology", Thessaloniki
Lead Sponsor
University Hospital of Crete
OTHER
Hellenic Oncology Research Group
OTHER